Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Immunocore Holdings (IMCR) is now available.
Immunocore Holdings plc announced promising results from its Phase 1 trial of a new cancer treatment, brenetafusp, for melanoma patients previously treated with immune checkpoints. The findings are set to be presented at the ASCO Annual Meeting and will be further discussed in a conference call and webcast. Investors and interested parties can access the webcast via the company’s website to learn about the potential impact on melanoma treatment.
For an in-depth examination of IMCR stock, go to TipRanks’ Stock Analysis page.
